CDXC 📈 Chromadex - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1710774076

CDXC: Dietary Supplements, NAD+ Boosters, Spirulina Extracts, Phytochemical Standards

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California. Web URL: https://www.chromadex.com

Additional Sources for CDXC Stock

CDXC Stock Overview

Market Cap in USD 470m
Sector Consumer Defensive
Industry Packaged Foods
GiC Sub-Industry Life Sciences Tools & Services
IPO / Inception 2008-07-15

CDXC Stock Ratings

Growth 5y 3.58%
Fundamental 7.73%
Dividend -
Rel. Strength Industry 5418
Analysts 4.6/5
Fair Price Momentum 5.78 USD
Fair Price DCF 1.35 USD

CDXC Dividends

No Dividends Paid

CDXC Growth Ratios

Growth Correlation 3m 68.2%
Growth Correlation 12m 72.6%
Growth Correlation 5y -52.2%
CAGR 5y 5.04%
CAGR/Mean DD 5y 0.08
Sharpe Ratio 12m 1.69
Alpha 255.13
Beta 0.88
Volatility 65.53%
Current Volume 1204.9k
Average Volume 20d 751k
What is the price of CDXC stocks?
As of December 21, 2024, the stock is trading at USD 5.49 with a total of 1,204,945 shares traded.
Over the past week, the price has changed by -10.29%, over one month by -26.80%, over three months by +51.24% and over the past year by +283.92%.
Is Chromadex a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Chromadex is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 7.73 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CDXC as of December 2024 is 5.78. This means that CDXC is currently overvalued and has a potential downside of 5.28%.
Is CDXC a buy, sell or hold?
Chromadex has received a consensus analysts rating of 4.60. Therefor, it is recommend to buy CDXC.
  • Strong Buy: 3
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for CDXC stock price target?
According to ValueRays Forecast Model, CDXC Chromadex will be worth about 6.4 in December 2025. The stock is currently trading at 5.49. This means that the stock has a potential upside of +16.58%.
Issuer Forecast Upside
Wallstreet Target Price 8 45%
Analysts Target Price 5.2 -5.8%
ValueRay Target Price 6.4 16.6%